文献速递白血病MDS 与骨髓增殖性肿瘤

PARP抑制在IDH1/2突变且对突变IDH1/2靶向抑制剂耐药的MDS/AML中的体内抗肿瘤效应

In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
PubMed 文献 · Leukemia · 2022-03-10

复发/难治性AML和MDS治疗选择有限,IDH1/2突变可用突变酶特异性小分子抑制剂(IDHmi)靶向,但单药不能治愈且常发生耐药。本研究在患者来源的IDH1/2突变AML/MDS异种移植模型中显示,PARP抑制剂奥拉帕利可有效减少总体植入和白血病起始细胞频率,且在IDHmi初治和耐药的AML模型中均有效。

要点

  • 奥拉帕利在IDH1/2突变AML/MDS患者来源异种移植模型中减少总体植入。
  • 奥拉帕利降低IDH1/2突变而非野生型AML/MDS异种移植的白血病起始细胞频率。
  • 奥拉帕利在IDHmi初治和耐药的AML异种移植模型中均有效。

核心结论

  • 临床前研究为将PARP抑制转化用于IDH1/2突变AML/MDS患者提供了有力依据,为对突变IDH靶向抑制无应答或复发后患者提供额外治疗选择。

研究设计与样本

  • 临床前研究,采用患者来源的IDH1/2突变和野生型AML/MDS异种移植模型(PDX),并进行连续移植实验。

主要发现

  • 奥拉帕利有效减少IDH1/2突变AML/MDS PDX的总体植入和白血病起始细胞频率,在连续移植实验中可见,而IDH1/2野生型PDX中未见此效应。
  • 奥拉帕利在IDHmi初治和IDHmi耐药的AML PDX中均有效。

临床怎么用

  • 作者认为这些临床前研究为将PARP抑制转化用于IDH1/2突变AML/MDS患者提供了有力依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment options for patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are scarce. Recurring mutations, such as mutations in isocitrate dehydrogenase-1 and -2 (IDH1/2) are found in subsets of AML and MDS, are therapeutically targeted by mutant enzyme-specific small molecule inhibitors (IDHmi). IDH mutations induce diverse metabolic and epigenetic changes that drive malignant transformation. IDHmi alone are not curative and resistance commonly develops, underscoring the importance of alternate therapeutic options. We were first to report that IDH1/2 mutations induce a homologous recombination (HR) defect, which confers sensitivity to poly (ADP)-ribose polymerase inhibitors (PARPi). Here, we show that the PARPi olaparib is effective against primary patient-derived IDH1/2-mutant AML/ MDS xeno-grafts (PDXs). Olaparib efficiently reduced overall engraftment and leukemia-initiating cell frequency as evident in serial transplantation assays in IDH1/2-mutant but not -wildtype AML/MDS PDXs. Importantly, we show that olaparib is effective in both IDHmi-naïve and -resistant AML PDXs, critical given the high relapse and refractoriness rates to IDHmi. Our pre-clinical studies provide a strong rationale for the translation of PARP inhibition to patients with IDH1/2-mutant AML/ MDS, providing an additional line of therapy for patients who do not respond to or relapse after targeted mutant IDH inhibition.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Gbyli R, Song Y, Liu W, et al. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia. 2022. PMID: 35273342. doi:10.1038/s41375-022-01536-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。